0 stringlengths 12 494 | embeddings listlengths 384 384 |
|---|---|
leaves only pharmaceutical inter-ventions (63). A recent guideline by theAmerican Academy of Neurology rec-ommends that the initial treatment ofpain should also focus on the concur-rent treatment of both sleep and mooddisorders because of increased frequencyof these problems in individuals withDPN (64). | [
0.02364400587975979,
-0.02339559979736805,
-0.046058326959609985,
0.05289966240525246,
-0.027836056426167488,
0.05349048599600792,
-0.047756753861904144,
0.05567505955696106,
0.07164955139160156,
-0.03830207511782646,
-0.04574236273765564,
0.050169363617897034,
-0.045344967395067215,
0.068... |
A number of pharmacologic therapies\nexist for treatment of pain in diabetes.The American Academy of Neurology\nupdate suggested that gabapentinoids, | [
-0.06937280297279358,
-0.03162394091486931,
-0.04947466030716896,
0.07368487119674683,
-0.15912780165672302,
0.046346183866262436,
0.05083642527461052,
0.09898868203163147,
0.030147911980748177,
0.013354533351957798,
-0.05928928405046463,
0.042506344616413116,
-0.024301519617438316,
0.0025... |
serotonin-norepinephrine reuptake in-hibitors (SNRIs), sodium channel block-ers, and tricyclic antidepressants (TCAs)could all be considered in the treatmentof pain in DPN (64). These AmericanAcademy of Neurology recommendationsoffer a supplement to a recent AmericanDiabetes Association pain monograph(65). A recent hea... | [
-0.06229163333773613,
-0.011946143582463264,
0.018853023648262024,
0.05177590250968933,
-0.1009930819272995,
0.05062791332602501,
0.014275692403316498,
0.0518178790807724,
0.040633052587509155,
-0.0392167903482914,
-0.08636516332626343,
0.06797371804714203,
-0.05555203929543495,
0.06685552... |
pain monograph(65). A recent head-to-head trial sug-gested therapeutic equivalency for TCAs,SNRIs, and gabapentinoids in the treat-ment of pain in DPN (66). The trial alsosupported the role of combination ther-apy over monotherapy for the treatmentof pain in DPN. | [
-0.11482315510511398,
-0.04137628525495529,
0.00913759134709835,
0.05096014216542244,
-0.15012727677822113,
0.04449637979269028,
0.0029188229236751795,
0.10893464088439941,
0.04492798447608948,
-0.013771641999483109,
-0.0014325549127534032,
0.08041556924581528,
0.013991420157253742,
0.0600... |
Gabapentinoids. Gabapentinoids include\nseveral calcium channel a2-dsubunit | [
-0.047044962644577026,
-0.050512105226516724,
-0.01254160888493061,
0.03752690926194191,
-0.1133626326918602,
-0.019740305840969086,
0.02348770573735237,
0.05545360967516899,
0.07033669203519821,
0.00012653376325033605,
0.06454725563526154,
-0.03768302500247955,
-0.0076688299886882305,
0.0... |
ligands. Eight high-quality studies andseven medium-quality studies supportthe role of pregabalin in treatment ofpain in DPN. One high-quality study andmany small studies support the role ofgabapentin in the treatment of pain inDPN. Two medium-quality studies sug-gest that mirogabalin has a small effecton pain in DPN (... | [
-0.07620476186275482,
-0.0864291787147522,
0.02304648980498314,
0.07488565146923065,
-0.11307504773139954,
0.045175936073064804,
-0.019783739000558853,
0.1567455679178238,
0.035531677305698395,
0.02312270551919937,
-0.06722469627857208,
0.06867192685604095,
-0.09790939092636108,
0.10340442... |
has a small effecton pain in DPN (64). Adverse effectsmay be more severe in older individu-als (67) and may be attenuated bylower starting doses and more gradualtitration. | [
-0.040437474846839905,
-0.08564655482769012,
0.05103575438261032,
0.023952346295118332,
-0.056746069341897964,
-0.017420276999473572,
-0.05486997216939926,
0.14698931574821472,
-0.03762964531779289,
-0.04706483706831932,
0.025451939553022385,
0.11769739538431168,
-0.007803427986800671,
0.0... |
SNRIs. SNRIs include duloxetine, venla-\nfaxine, and desvenlafaxine, all selectiveSNRIs. Two high-quality studies and fivemedium-quality studies support the role\nof duloxetine in the treatment of painin DPN. A high-quality study supportsthe role of venlafaxine in the treatment\nof pain in DPN. Only one medium-quality | [
-0.0800720676779747,
-0.08771509677171707,
-0.02538297139108181,
0.009694731794297695,
-0.05882047116756439,
0.006937354803085327,
-0.069427989423275,
0.1218189001083374,
0.031146060675382614,
-0.036601416766643524,
-0.031680796295404434,
0.0912213921546936,
0.0017416357295587659,
0.086045... |
of pain in DPN. Only one medium-quality\nstudy supports a possible role for des-venlafaxine for treatment of pain in DPN(64). Adverse events may be more severe\nin older people but may be attenuated\nwith lower doses and slower titration ofduloxetine.\nTapentadol and Tramadol. Tapentadol | [
-0.019109824672341347,
-0.06530589610338211,
0.016333166509866714,
0.023655636236071587,
-0.08296848833560944,
-0.010242081247270107,
-0.0218239463865757,
0.1834874004125595,
-0.015267577953636646,
-0.05831873044371605,
-0.0012936079874634743,
0.09699773788452148,
-0.00111000903416425,
0.0... |
Tapentadol and Tramadol. Tapentadol\nand tramadol are centrally acting opioidanalgesics that exert their analgesic ef-\nfects through both m-opioid receptor\nagonism and norepinephrine and sero-\ntonin reuptake inhibition. SNRI/opioid\nagents are probably effective in the | [
0.026071932166814804,
-0.09067671000957489,
-0.06211671233177185,
0.05820314958691597,
0.02368345856666565,
0.007423014845699072,
-0.046194471418857574,
0.09489790350198746,
0.02041606977581978,
0.004574863240122795,
0.0634339228272438,
0.05421173945069313,
-0.06401442736387253,
0.09640017... |
agents are probably effective in the\ntreatment of pain in DPN. However,the use of any opioids for manage-ment of chronic neuropathic pain car-\nries the risk of addiction and should\nbe avoided.\nTricyclic Antidepressants. TCAs have been | [
-0.05677099525928497,
-0.022861575707793236,
0.002260526642203331,
0.059681426733732224,
-0.09578490257263184,
0.04463895037770271,
-0.022389808669686317,
0.15488547086715698,
0.046657055616378784,
-0.040763139724731445,
-0.002002791501581669,
0.10090941190719604,
0.0014885979471728206,
0.... |
be avoided.\nTricyclic Antidepressants. TCAs have been\nstudied for treatment of pain, and mosto ft h er e l e v a n td a t aw e r ea c q u i r e df r o mtrials of amitriptyline and include two\nhigh-quality studies and two medium-\nquality studies supporting the treatmentof pain in DPN (64,66). Anticholinergicside eff... | [
-0.05749070644378662,
0.02000044472515583,
0.04648789018392563,
0.05240287259221077,
-0.10617382824420929,
0.029383134096860886,
-0.03067428432404995,
0.14559826254844666,
0.037655703723430634,
0.0023914247285574675,
-0.03152221068739891,
0.03236957639455795,
0.013715481385588646,
0.035760... |
restrict use in individuals $65 years of\nage.\nSodium Channel Blockers. Sodium chan-\nnel blockers include lamotrigine, lacosa-\nmide, carbamazepine, oxcarbazepine,and valproic acid. Five medium-quality\nstudies support the role of sodium\nchannel blockers in treating pain inDPN (64).\nCapsaicin. Capsaicin has receive... | [
-0.06668280065059662,
-0.037596192210912704,
0.008944815024733543,
0.0068398877047002316,
-0.017410824075341225,
0.015347962267696857,
-0.03712277486920357,
0.16331639885902405,
-0.005058113019913435,
-0.0690070167183876,
0.018723949790000916,
0.006255328189581633,
0.03234194591641426,
0.0... |
Capsaicin. Capsaicin has received FDA\napproval for treatment of pain in DPNusing an 8% patch, with one high-quality\nstudy reported. One medium-quality study\nof 0.075% capsaicin cream has been re-ported. In individulas with contraindica-tions to oral pharmacotherapy or who\nprefer topical treatments, the use of topi-... | [
-0.024759484454989433,
-0.059537868946790695,
-0.04273455962538719,
0.007809165865182877,
-0.05545062571763992,
-0.006485977675765753,
-0.029649903997778893,
0.17645765841007233,
0.0007944009848870337,
-0.029007885605096817,
0.027779899537563324,
-0.002847851486876607,
0.044310133904218674,
... |
cal capsaicin can be considered.\nLidocaine 5% Plaster/Patch. Lidocaine\npatches have limited data supportingtheir use in DPN and are not effectivein more widespread distribution of pain\n(although they may be of use in individ-\nuals with nocturnal neuropathic footpain). Lidocaine patches cannot be used\nfor more than... | [
0.013266720809042454,
-0.05818341299891472,
-0.01707206480205059,
0.04007023572921753,
-0.029883336275815964,
-0.012432566843926907,
-0.011747121810913086,
0.12855137884616852,
0.022013628855347633,
-0.03252590447664261,
0.005040181800723076,
0.004971241112798452,
0.03106973133981228,
0.13... |
for more than 12 h in a 24-h period\n(68).S236 Retinopathy, Neuropathy, and Foot Care Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.0026971467304974794,
-0.02382740005850792,
-0.053403206169605255,
0.029921798035502434,
-0.004329579882323742,
0.021273300051689148,
-0.05156208947300911,
0.11403921991586685,
-0.10290683060884476,
-0.027748161926865578,
0.022699736058712006,
0.021023936569690704,
-0.028034811839461327,
... |
a-Lipoic Acid. a-Lipoic acid, although not\napproved for the treatment of painful\nDPN, may be effective and considered\nfor the treatment of painful DPN (64,65).\nOrthostatic Hypotension | [
-0.07871031761169434,
-0.048541110008955,
-0.03217703849077225,
0.04792315885424614,
-0.11426187306642532,
0.059719864279031754,
-0.029484238475561142,
0.13638325035572052,
0.010442987084388733,
-0.03234017267823219,
0.04275251552462578,
-0.010944696143269539,
-0.06246419623494148,
0.10247... |
Orthostatic Hypotension\nTreating orthostatic hypotension is chal-lenging. The therapeutic goal is to mini-mize postural symptoms rather than torestore normotension. Most individualsrequire both nonpharmacologic meas-ures (e.g., ensuring adequate salt intake,avoiding medications that aggravate hy-potension, or using co... | [
-0.051258280873298645,
0.004053890705108643,
-0.003610118990764022,
0.03872247785329819,
-0.06034119427204132,
0.02484532818198204,
0.05499475449323654,
0.13751810789108276,
0.051195040345191956,
-0.01711033098399639,
0.03175944462418556,
0.02022234909236431,
0.0508955642580986,
0.03828009... |
ments over the legs and abdomen) and\npharmacologic measures. Physical activ-ity and exercise should be encouragedto avoid deconditioning, which is knownto exacerbate orthostatic intolerance,and volume repletion with fluids and\nsalt is critical. There have been clinicalstudies that assessed the impact of an\napproach i... | [
0.028381306678056717,
-0.03428231552243233,
-0.0014180622529238462,
0.04684858396649361,
-0.08658502250909805,
-0.04133033752441406,
0.049797095358371735,
0.12025806307792664,
-0.014649713411927223,
0.036831896752119064,
0.028910011053085327,
0.030465522781014442,
0.013609902001917362,
0.0... |
tioned nonpharmacologic measures. Ad-ditionally, supine blood pressure tendsto be much higher in these individuals,often requiring treatment of blood pres-sure at bedtime with shorter-acting drugsthat also affect baroreceptor activity suchas guanfacine or clonidine, shorter-actingcalcium blockers (e.g., isradipine), or | [
-0.014632387086749077,
-0.06939876824617386,
-0.07769563794136047,
-0.0023809620179235935,
-0.007077495567500591,
0.015877829864621162,
0.03351626917719841,
0.09424930065870285,
0.07298314571380615,
-0.02285480871796608,
0.04995346814393997,
-0.035946402698755264,
-0.0012348988093435764,
0... |
shorter-acting b- b l o c k e r ss u c ha sa t e n o -\nlol or metoprolol tartrate. Alternatives\ncan include enalapril if an individual isunable to tolerate preferred agents(69–71). Midodrine and droxidopa are\napproved by the FDA for the treat-ment of orthostatic hypotension.\nGastroparesis | [
-0.02144644968211651,
0.03605332970619202,
-0.00805461686104536,
0.03470999374985695,
-0.048003748059272766,
0.06288004666566849,
-0.02464206889271736,
0.1790114939212799,
0.02014240249991417,
-0.07213623821735382,
0.027174392715096474,
-0.012989393435418606,
0.0025252525229007006,
0.00270... |
Gastroparesis\nTreatment for diabetic gastroparesis maybe very challenging. A low- fiber, low-fat\neating plan provided in small frequentmeals with a greater proportion of liquid\ncalories may be useful (72 –74). In addi-\ntion, foods with small particle size may | [
0.028620949015021324,
-0.012904398143291473,
-0.015749454498291016,
0.08021174371242523,
-0.055971890687942505,
-0.014587074518203735,
0.028074603527784348,
0.08488395810127258,
-0.07798700779676437,
-0.04826173558831215,
-0.04801587015390396,
-0.01564170978963375,
-0.11293504387140274,
0.... |
tion, foods with small particle size may\nimprove key symptoms (75). Withdraw-ing drugs with adverse effects on gastro-intestinal motility, including opioids,anticholinergics, TCAs, GLP-1 RAs, andpramlintide, may also improve intestinalmotility (72,76). However, the risk of re-moval of GLP-1 RAs should be balanced | [
0.002260772977024317,
-0.047221776098012924,
-0.05125904083251953,
0.09090593457221985,
-0.0444229431450367,
-0.03435596451163292,
0.052094921469688416,
0.10872902721166611,
-0.039336204528808594,
-0.06209166720509529,
0.035798121243715286,
0.058208879083395004,
-0.01720242016017437,
0.085... |
against their potential bene fits. In cases\nof severe gastroparesis, pharmacologic\ninterventions are needed. Only metoclo-pramide, a prokinetic agent, is approvedby the FDA for the treatment of gastro-paresis. However, the level of evidenceregarding the bene fits of metoclopra-\nmide for the management of gastropare- | [
-0.041137855499982834,
-0.02365955151617527,
-0.10863623768091202,
-0.02616223692893982,
-0.03764132037758827,
0.02321377769112587,
0.03716728836297989,
0.2164505571126938,
-0.005749195348471403,
0.009532568044960499,
0.017590558156371117,
0.04108879715204239,
-0.042442940175533295,
0.0291... |
mide for the management of gastropare-\nsis is weak, and given the risk for seriousadverse effects (extrapyramidal signs suchas acute dystonic reactions, drug-inducedparkinsonism, akathisia, and tardive dyski-nesia), its use in the treatment of gastro-\nparesis beyond 12 weeks is no longer | [
-0.029207007959485054,
-0.028261877596378326,
-0.00036249915137887,
-0.024760907515883446,
0.027299173176288605,
-0.04066126048564911,
-0.04385757073760033,
0.24381327629089355,
0.012947254814207554,
-0.00891590490937233,
-0.022813979536294937,
0.0822005495429039,
-0.03455827757716179,
0.0... |
paresis beyond 12 weeks is no longer\nrecommended by the FDA. It should bereserved for severe cases that are unre-sponsive to other therapies (76). Othertreatment options include domperidone(available outside the U.S.) and erythro-mycin, which is only effective for short-\nterm use due to tachyphylaxis (77,78). | [
0.017185095697641373,
-0.04016018658876419,
-0.04189646244049072,
-0.046851061284542084,
-0.024686582386493683,
0.0017169099301099777,
-0.07771456986665726,
0.17364123463630676,
-0.057112887501716614,
0.002507374854758382,
0.011181863024830818,
0.09486286342144012,
-0.10381199419498444,
-0... |
term use due to tachyphylaxis (77,78).\nGastric electrical stimulation using a surgi-cally implantable device has received ap-proval from the FDA, although there arevery limited data in DPN and the resultsdo not support gastric stimulation as an\neffective therapy in diabetic gastroparesis\n(79).\nErectile Dysfunction | [
-0.04309451952576637,
-0.04758438840508461,
-0.02425825409591198,
0.058914072811603546,
-0.14591863751411438,
-0.02568751387298107,
0.1059817522764206,
0.16532744467258453,
-0.0023086839355528355,
-0.006080895196646452,
0.028160318732261658,
0.046329498291015625,
-0.04414167255163193,
0.07... |
(79).\nErectile Dysfunction\nIn addition to treatment of hypogonad-ism if present, treatments for erectiledysfunction may include phosphodies-terase type 5 inhibitors, intracorporeal\nor intraurethral prostaglandins, vacuum | [
-0.028615828603506088,
0.01910961978137493,
0.039552368223667145,
0.07284699380397797,
-0.10906510055065155,
0.01909864880144596,
0.04409286007285118,
0.12949620187282562,
-0.04269660636782646,
0.053513236343860626,
0.000152297128806822,
0.03876737505197525,
-0.09237699210643768,
0.0534378... |
or intraurethral prostaglandins, vacuum\ndevices, or penile prostheses. As withDPN treatments, these interventions donot change the underlying pathologyand natural history of the disease pro-cess but may improve a person ’sq u a l i t y\nof life.\nFOOT CARE\nRecommendations\n12.23 Perform a comprehensive foot\nevaluati... | [
-0.07959892600774765,
-0.0007694131345488131,
0.04510246589779854,
-0.007052044849842787,
-0.08442597836256027,
-0.041734155267477036,
-0.0037782436702400446,
0.1365133672952652,
-0.04185990244150162,
0.05421128123998642,
0.046597447246313095,
0.07873456925153732,
-0.04880474880337715,
0.0... |
evaluation at least annually to iden-\ntify risk factors for ulcers and ampu-tations. A\n12.24 The examination should include in-\nspection of the skin, assessment of footdeformities, neurological assessment(10-g mono filament testing with at\nleast one other assessment: pinprick,temperature, or vibration), and vas- | [
0.002388656372204423,
0.026872439309954643,
0.026742136105895042,
0.030691741034388542,
-0.06118883937597275,
-0.011324787512421608,
0.00187229725997895,
0.09970961511135101,
-0.06802976876497269,
-0.007097145542502403,
0.06101924926042557,
-0.05830993130803108,
-0.005088514182716608,
0.02... |
cular assessment, including pulses in\nthe legs and feet. B\n12.25 Individuals with evidence of\nsensory loss or prior ulceration oramputation should have their feetinspected at every visit. A\n12.26 Obtain a prior history of ulcera-\ntion, amputation, Charcot foot, angio-plasty or vascular surgery, cigarette\nsmoking,... | [
-0.035136401653289795,
0.005537775810807943,
0.03277154266834259,
0.015730364248156548,
-0.05521462857723236,
-0.009598634205758572,
-0.005317170638591051,
0.103973388671875,
-0.08600203692913055,
0.022817175835371017,
0.045209188014268875,
-0.04593989625573158,
-0.03938179835677147,
0.024... |
smoking, retinopathy, and renal dis-\nease and assess current symptoms ofneuropathy (pain, burning, numbness)and vascular disease (leg fatigue, clau-dication). B\n12.27 Initial screening for peripheral\narterial disease (PAD) should in-clude assessment of lower-extremitypulses, capillary re fill time, rubor on | [
-0.026399236172437668,
-0.029269080609083176,
-0.0142231909558177,
-0.03968265652656555,
0.00944171566516161,
-0.030292661860585213,
0.024524280801415443,
0.13041669130325317,
-0.023936379700899124,
0.04903552681207657,
0.04339475929737091,
0.01959063857793808,
-0.01614348031580448,
0.0402... |
dependency, pallor on elevation, andvenous filling time. Individuals with\na history of leg fatigue, claudication,and rest pain relieved with depen-dency or decreased or absent pedalpulses should be referred for ankle-brachial index with toe pressures andfor further vascular assessment asappropriate. B\n12.28 An interpr... | [
-0.04642873629927635,
0.01906692422926426,
0.0037454382982105017,
0.029642615467309952,
-0.03390783816576004,
-0.004757694900035858,
0.03098113089799881,
0.0735575407743454,
-0.025686250999569893,
-0.010652822442352772,
0.041534923017024994,
0.02045368030667305,
0.0048162927851080894,
0.05... |
12.28 An interprofessional approach\nfacilitated by a podiatrist in conjunctionwith other appropriate team membersis recommended for individuals withfoot ulcers and high-risk feet (e.g.,those on dialysis, those with Charcotfoot, those with a history of prior ulcersor amputation, and those with PAD). B\n12.29 Refer indi... | [
-0.02882261574268341,
0.03641015663743019,
0.03426751494407654,
0.018313394859433174,
-0.06509451568126678,
-0.017969409003853798,
0.028195783495903015,
0.0770288035273552,
-0.01174694113433361,
-0.019802436232566833,
0.06899018585681915,
0.04551615193486214,
-0.026962218806147575,
-0.0019... |
12.29 Refer individuals who smoke\nand have a history of prior lower-extremity complications, loss of pro-tective sensation, structural abnormal-ities, or PAD to foot care specialists forongoing preventive care and lifelongsurveillance. B\n12.30 Provide general preventive foot | [
-0.02331331931054592,
0.036665432155132294,
0.040893908590078354,
-0.02278328500688076,
-0.020031733438372612,
0.035366419702768326,
0.014686311595141888,
0.09730318188667297,
-0.02593490295112133,
0.038645241409540176,
0.07321662455797195,
0.009371541440486908,
-0.028589999303221703,
-0.0... |
12.30 Provide general preventive foot\nself-care education to all people withdiabetes, including those with loss ofprotective sensation, on appropriate\nways to examine their feet (palpation\nor visual inspection with an unbreak-able mirror) for daily surveillance ofearly foot problems. B\n12.31 The use of specialized ... | [
-0.07599842548370361,
0.06092030555009842,
0.015526137314736843,
-0.03670911490917206,
-0.014302338473498821,
0.01513376459479332,
0.04491706192493439,
0.08780638128519058,
-0.07520166784524918,
0.07652440667152405,
0.04278210923075676,
0.033518243581056595,
-0.06961974501609802,
0.0332448... |
12.31 The use of specialized thera-\npeutic footwear is recommended forpeople with diabetes at high risk forulceration, including those with lossof protective sensation, foot deformi-ties, ulcers, callous formation, poorperipheral circulation, or history ofamputation. B\n12.32 For chronic diabetic foot ulcers | [
-0.10212156176567078,
0.03455490991473198,
-0.033122263848781586,
0.00247532338835299,
-0.03463679552078247,
0.014289316721260548,
0.06876076757907867,
0.0988360345363617,
-0.09010916948318481,
0.04244674742221832,
0.0330268032848835,
0.07459122687578201,
-0.07207004725933075,
0.0162953101... |
12.32 For chronic diabetic foot ulcers\nthat have failed to heal with optimalstandard care alone, adjunctive treat-ment with randomized controlled trial – | [
-0.03562668710947037,
0.019366493448615074,
-0.022937394678592682,
0.04500693455338478,
-0.02399500086903572,
-0.02163700945675373,
0.019901297986507416,
0.08819552510976791,
-0.04393750801682472,
-0.06676512956619263,
0.021949416026473045,
0.05714017152786255,
-0.07648249715566635,
-0.045... |
proven advanced agents should beconsidered. Considerations might in-clude negative-pressure wound therapy,placental membranes, bioengineeredskin substitutes, several acellular ma-trices, autologous fibrin and leukocyte\nplatelet patches, and topical oxygen\ntherapy. Adiabetesjournals.org/care Retinopathy, Neuropathy, an... | [
-0.05262112617492676,
-0.05881001055240631,
0.026487302035093307,
0.00010512966400710866,
0.0017116046510636806,
0.02749188058078289,
-0.015836074948310852,
0.12779691815376282,
-0.0770888701081276,
0.09784494340419769,
0.040523432195186615,
-0.007719297893345356,
-0.09167324006557465,
0.1... |
©AmericanDiabetesAssociation | [
0.06342031806707382,
-0.04462772607803345,
-0.07223597913980484,
0.043682683259248734,
-0.045854225754737854,
-0.0014199750730767846,
-0.005912777967751026,
-0.07833275198936462,
-0.04720243066549301,
0.09212949872016907,
0.0628901943564415,
-0.04908110201358795,
0.0067015099339187145,
0.0... |
Foot ulcerations and amputations are com-\nmon complications associated with diabe-\ntes. These may be the consequences of\nseveral factors, including peripheral neu-\nropathy, peripheral arterial disease (PAD),and foot deformities. They represent major\ncauses of morbidity and mortality in peo- | [
-0.002544648014008999,
0.033495865762233734,
0.0290085282176733,
-0.019893163815140724,
-0.024778729304671288,
-0.02605438604950905,
-0.012175933457911015,
0.07191010564565659,
-0.03860799968242645,
0.036316365003585815,
0.05828017368912697,
0.008507505990564823,
0.00013914916780777276,
0.... |
causes of morbidity and mortality in peo-\nple with diabetes. Early recognition of at-risk feet, preulcerative lesions, and prompt\ntreatment of ulcerations and other lower-\nextremity complications can delay or pre-\nvent adverse outcomes.\nEarly recognition requires an under-\nstanding of those factors that put peo- | [
0.005459018517285585,
0.040945667773485184,
0.02672552689909935,
0.014835949055850506,
-0.014466640539467335,
-0.0063884505070745945,
0.04163799434900284,
0.11929924786090851,
0.00042838146327994764,
0.05157165229320526,
0.03153195604681969,
0.024601956829428673,
-0.02426125667989254,
-0.0... |
standing of those factors that put peo-\nple with diabetes at increased risk for\nulcerations and amputations. Factors\nthat are associated with the at-risk footinclude the following:\n\x81Poor glycemic management\n\x81Peripheral neuropathy/LOPS\n\x81PAD\n\x81Foot deformities (bunions, hammer-\ntoes, Charcot joint, etc... | [
-0.037726931273937225,
-0.004722995683550835,
0.015342616476118565,
0.05289653688669205,
0.003932750318199396,
-0.00498259486630559,
0.06843306124210358,
0.1246323436498642,
-0.06515627354383469,
0.033414214849472046,
0.06778981536626816,
0.039835598319768906,
-0.02730114944279194,
-0.0034... |
toes, Charcot joint, etc.)\n\x81Preulcerative corns or calluses\n\x81Prior ulceration\n\x81Prior amputation\n\x81Smoking\n\x81Retinopathy\n\x81Nephropathy (particularly individuals\non dialysis or posttransplant)\nIdentifying the at-risk foot begins\nwith a detailed history documenting di-\nabetes management, smoking h... | [
-0.03978493809700012,
-0.007372457999736071,
0.03197266533970833,
0.0565236397087574,
-0.0770450085401535,
-0.02761688083410263,
-0.02259804494678974,
0.09869778901338577,
-0.06545756012201309,
0.0482802614569664,
0.08967489749193192,
0.0625690445303917,
-0.011902784928679466,
-0.000549235... |
abetes management, smoking history,\nexercise tolerance, history of claudica-tion or rest pain, and prior ulcerations\nor amputations. A thorough examina-\ntion of the feet should be performed\nannually in all people with diabetes and\nmore frequently in at-risk individuals(80). The examination should includeassessment... | [
-0.021540876477956772,
0.09968644380569458,
0.01129929255694151,
0.020115770399570465,
-0.09341759234666824,
-0.01316881738603115,
0.018689990043640137,
0.06238445267081261,
-0.09443981200456619,
0.005422774702310562,
-0.009714354760944843,
0.024364732205867767,
-0.05791405215859413,
0.044... |
for LOPS using the 10-g mono filament\nalong with at least one other neurologi-cal assessment tool, pulse examination\nof the dorsalis pedis and posterior tibial\narteries, and assessment for foot deformi-ties such as bunions, hammertoes, and\nprominent metatarsals, which increase | [
-0.05335761979222298,
-0.034006256610155106,
0.06867711246013641,
-0.08454827219247818,
-0.07178106158971786,
-0.0490838959813118,
0.011758402921259403,
0.09097478538751602,
-0.05013533681631088,
0.03626735135912895,
0.05073688179254532,
-0.0005583555903285742,
-0.06279269605875015,
0.0402... |
prominent metatarsals, which increase\nplantar foot pressures and increase riskfor ulcerations. At-risk individuals should\nbe assessed at each visit and should be\nreferred to foot care specialists for ongo-ing preventive care and surveillance. The\nphysical examination can stratify people | [
0.021370025351643562,
0.024803899228572845,
0.009973153471946716,
0.028494495898485184,
0.0139832254499197,
-0.006538189481943846,
0.006717306096106768,
0.10968746989965439,
-0.05951417610049248,
0.062329817563295364,
0.02828601375222206,
0.036540400236845016,
-0.07546905428171158,
0.03490... |
physical examination can stratify people\nwith diabetes into different categoriesand determine the frequency of these vis-\nits (81) ( Table 12.1 ).\nEvaluation for Loss of Protective\nSensation\nThe presence of peripheral sensory neu-\nropathy is the single most common\ncomponent cause for foot ulceration. Ina multice... | [
0.048897676169872284,
-0.01464092917740345,
-0.013138161972165108,
0.029367730021476746,
-0.039760053157806396,
0.01106942631304264,
0.03276130184531212,
0.06705676764249802,
-0.059264879673719406,
0.04243776574730873,
0.027451753616333008,
0.030459312722086906,
-0.0579630471765995,
0.0361... |
thy was found to be a component cause\nin 78% of people with diabetes with ul-cerations and that the triad of periph-\neral sensory neuropathy, minor trauma,\nand foot deformity was present in>63% of participants (82). All people | [
-0.01428261213004589,
0.01011252123862505,
-0.014019044116139412,
0.05612083896994591,
0.004150770138949156,
0.012171733193099499,
0.051976773887872696,
0.10300123691558838,
-0.008787744678556919,
0.05441516637802124,
0.054467782378196716,
0.033506106585264206,
-0.02430826425552368,
0.0036... |
with diabetes should undergo a com-prehensive foot examination at least an-nually, or more frequently for those inhigher-risk categories (80,81).\nLOPS is vital to risk assessment. One\nof the most useful tests to determineLOPS is the 10-g mono filament test.\nStudies have shown that clinical exami-nation and the 10-g m... | [
-0.02073964849114418,
0.042185425758361816,
0.010924486443400383,
-0.0035160782281309366,
-0.05146287754178047,
-0.018951300531625748,
0.03479529544711113,
0.0940556600689888,
-0.03189462050795555,
0.03639331832528114,
-0.008258395828306675,
0.015132800675928593,
-0.08770638704299927,
0.09... |
are the two most sensitive tests in iden-tifying the foot at risk for ulceration\n(83). The mono filament test should beperformed with at least one other neu-\nrologic assessment tool (e.g., pinprick,temperature perception, ankle re flexes,\nor vibratory perception with a 128-Hztuning fork or similar device). Absentmono ... | [
-0.024624308571219444,
-0.04919877648353577,
0.030321946367621422,
0.009853473864495754,
0.017880642786622047,
-0.08188216388225555,
0.062327004969120026,
0.1103806272149086,
-0.06098622828722,
0.04356323182582855,
0.06288234144449234,
-0.02214212529361248,
0.004370963666588068,
0.07994832... |
abnormal test con firms the presence of\nLOPS. Further neurological testing, suchas nerve conduction, electromyography,nerve biopsy, or intraepidermal nervefiber density biopsies, are rarely indi-\ncated for the diagnosis of peripheral\nsensory neuropathy (46).\nEvaluation for Peripheral Arterial\nDisease\nInitial screen... | [
-0.021898653358221054,
-0.06103004887700081,
-0.016643589362502098,
-0.006766317877918482,
-0.01781514845788479,
-0.07991165667772293,
0.042505133897066116,
0.06801211833953857,
-0.026578418910503387,
0.021891875192523003,
0.09607540816068649,
0.0017283291090279818,
-0.027491822838783264,
... |
Disease\nInitial screening for PAD should include\na history of leg fatigue, claudication,\nand rest pain relieved with dependency.\nPhysical examination for PAD should in-clude assessment of lower-extremitypulses, capillary re fill time, rubor on de-\npendency, pallor on elevation, and ve-\nnous filling time (80,84). An... | [
-0.03441987559199333,
-0.029513876885175705,
-0.044487904757261276,
-0.043333087116479874,
0.0012008752673864365,
-0.03610333055257797,
0.00855248048901558,
0.10883995145559311,
-0.024465937167406082,
0.01847940683364868,
0.071956105530262,
0.014857607893645763,
-0.03562614694237709,
0.096... |
nous filling time (80,84). Any individual\nexhibiting signs and symptoms of PAD\nshould be referred for noninvasive arterialstudies in the form of Doppler ultrasoundwith pulse volume recordings. Whileankle-brachial indices will be calculated,\nthey should be interpreted carefully, as | [
0.07521510124206543,
-0.05128126218914986,
-0.051857840269804,
-0.008177706971764565,
-0.020964697003364563,
-0.0605580098927021,
0.013674410060048103,
0.00820054579526186,
0.023059112951159477,
-0.08146140724420547,
0.09826333075761795,
-0.043622780591249466,
-0.031941238790750504,
0.0468... |
they should be interpreted carefully, as\nthey are known to be inaccurate in peo-ple with diabetes due to noncompressiblevessels. Toe systolic blood pressure tendsto be more accurate. Toe systolic bloodpressures <30 mmHg are suggestive of | [
-0.00826310645788908,
-0.003322978736832738,
-0.024381689727306366,
-0.03522605448961258,
-0.08089099079370499,
-0.027110643684864044,
0.014065341092646122,
0.037456050515174866,
0.028944894671440125,
-0.03559987619519234,
0.011126135475933552,
0.00417905580252409,
-0.02937932126224041,
-0... |
PAD and an inability to heal foot ulcera-tions (85). Individuals with abnormal pulsevolume recording tracings and toe pres-sures<30 mmHg with foot ulcers should\nbe referred for immediate vascular eval-uation. Due to the high prevalence of\nPAD in people with diabetes, the Society | [
-0.03796420246362686,
-0.04542180523276329,
-0.04634451866149902,
0.057048190385103226,
0.0011408786522224545,
-0.03121800720691681,
0.034163281321525574,
0.07161669433116913,
-0.0177615974098444,
0.009048577398061752,
0.11367858201265335,
0.019812149927020073,
-0.0485348142683506,
-0.0037... |
PAD in people with diabetes, the Society\nTable 12.1 —International Working Group on the Diabetic Foot risk strati fication system and corresponding foot screening\nfrequency\nCategory Ulcer risk Characteristics Examination frequency*\n0 Very low No LOPS and No PAD Annually\n1 Low LOPS or PAD Every 6–12 months\n2 Modera... | [
0.009715398773550987,
-0.0312056727707386,
-0.07554366439580917,
-0.02459254115819931,
0.015229890123009682,
-0.03095376491546631,
0.03223160281777382,
0.0925043597817421,
0.0033537554554641247,
-0.03918395936489105,
0.0786038190126419,
0.04814331233501434,
-0.04595700278878212,
-0.0158156... |
1 Low LOPS or PAD Every 6–12 months\n2 Moderate LOPS1PAD, or\nLOPS1foot deformity, or\nPAD1foot deformityEvery 3 –6 months\n3 High LOPS or PAD and one or more of the following:\n/C15History of foot ulcer\n/C15Amputation (minor or major)\n/C15End-stage renal diseaseEvery 1 –3 months | [
-0.025672152638435364,
-0.06703387200832367,
0.04115229472517967,
-0.007767076604068279,
-0.03552725166082382,
-0.08282630145549774,
-0.06374701857566833,
0.11758635193109512,
-0.018214071169495583,
-0.051169171929359436,
0.054144781082868576,
0.016018204391002655,
0.013599537312984467,
-0... |
/C15End-stage renal diseaseEvery 1 –3 months\nAdapted with permission from Schaper et al. (81). LOPS, loss of protective sensation; PAD, peripheral artery disease. *Examination frequency | [
-0.04627564549446106,
-0.0172782763838768,
0.06590753048658371,
-0.025077901780605316,
-0.042154379189014435,
-0.0906982347369194,
-0.04189576953649521,
0.1255180686712265,
-0.0012928214855492115,
-0.006617607548832893,
-0.016525793820619583,
0.002705235034227371,
-0.01809416338801384,
0.0... |
suggestions are based on expert opinion and person-centered requirements.S238 Retinopathy, Neuropathy, and Foot Care Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.06462318450212479,
-0.06413884460926056,
0.009368962608277798,
0.00007524951797677204,
-0.03375198692083359,
0.044490206986665726,
-0.048016440123319626,
0.08552266657352448,
-0.11064674705266953,
-0.03378415107727051,
-0.02234857901930809,
0.02803402580320835,
-0.06299342215061188,
0.0... |
for Vascular Surgery and the American\nPodiatric Medical Association guidelines\nrecommend that all people with diabe-tes>50 years of age should undergo\nscreening via noninvasive arterial studies(84,86). If normal, these should be re-peated every 5 years (84).\nEducation for People With Diabetes | [
0.03527849540114403,
0.097632497549057,
-0.04127174988389015,
-0.05627024546265602,
-0.0643734335899353,
-0.05870881676673889,
-0.007069262210279703,
0.028437484055757523,
-0.08424501121044159,
-0.004084322135895491,
-0.0063293674029409885,
0.0623302087187767,
-0.05289177969098091,
0.07483... |
Education for People With Diabetes\nAll people with diabetes (and their fami-lies), particularly those with the afore-mentioned high-risk conditions, shouldreceive general foot care education, in-\ncluding appropriate management strate-\ngies (87 –89). This education should be | [
-0.0072121694684028625,
0.026916926726698875,
0.002123396610841155,
0.017975902184844017,
-0.05947862192988396,
0.009904640726745129,
0.062129851430654526,
0.02551283873617649,
-0.07035946846008301,
0.04180695489048958,
-0.01775728352367878,
0.08901173621416092,
-0.10345099866390228,
0.017... |
gies (87 –89). This education should be\nprovided to all newly diagnosed peoplewith diabetes as part of an annual com-prehensive examination and to individu-als with high-risk conditions at everyvisit. Recent studies have shown thatwhile education improves knowledge ofdiabetic foot problems and self-care ofthe foot, it... | [
-0.013250277377665043,
0.007844916544854641,
0.011362039484083652,
0.05205275118350983,
-0.111182302236557,
-0.006511413026601076,
0.062103115022182465,
0.07269352674484253,
-0.02795260213315487,
0.06280411779880524,
-0.019328702241182327,
0.12171342968940735,
-0.0076403082348406315,
0.003... |
associated with active participation in\ntheir overall diabetes care and to achievepersonal health goals (90). Evidence alsosuggests that while education for peoplewith diabetes and their families is impor-tant, the knowledge is quickly forgottenand needs to be reinforced regularly (91).\nIndividuals considered at risk... | [
0.026716602966189384,
0.11949943006038666,
-0.06229604408144951,
0.06739918142557144,
-0.0073893992230296135,
0.11072223633527756,
0.09982694685459137,
0.03825864568352699,
-0.0709800198674202,
-0.003961764741688967,
0.016371075063943863,
0.0783192366361618,
-0.035762760788202286,
0.000426... |
Individuals considered at risk should\nunderstand the implications of foot de-formities, LOPS, and PAD; the proper\ncare of the foot, including nail and skin | [
-0.07124832272529602,
0.07528402656316757,
0.002513084327802062,
-0.05084582790732384,
0.039898619055747986,
0.011131435632705688,
0.03166460618376732,
0.10115554928779602,
-0.08932811766862869,
0.0415535569190979,
0.12639154493808746,
0.023284951224923134,
-0.02680034749209881,
0.02718072... |
care; and the importance of foot inspec-tions on a daily basis. Individuals withLOPS should be educated on appropriateways to examine their feet (palpation orvisual inspection with an unbreakablemirror) for daily surveillance of early footproblems. People with diabetes shouldalso be educated on the importance ofreferra... | [
-0.0745120570063591,
0.05182242766022682,
0.024567222222685814,
-0.0001746814523357898,
-0.014838519506156445,
0.015652187168598175,
0.1021624282002449,
0.05900651961565018,
-0.057838309556245804,
0.02005559764802456,
0.002642818493768573,
0.0561152920126915,
-0.07128521054983139,
0.051004... |
be educated on the importance ofreferrals to foot care specialists. A recent | [
-0.03251681104302406,
-0.03730951249599457,
0.038470711559057236,
0.03958873450756073,
-0.03862513229250908,
0.0217747762799263,
-0.0006451126537285745,
0.08263067156076431,
-0.025351498275995255,
0.024908289313316345,
-0.032150618731975555,
0.06320031732320786,
-0.02418673224747181,
0.077... |
study showed that people with diabetes\nand foot disease lacked awareness oftheir risk status and why they were be-ing referred to a interprofessional teamof foot care specialists. Further, they ex-hibited a variable degree of interest inlearning further about foot complications(92).\nIndividuals ’understanding of thes... | [
-0.031021449714899063,
0.05359581857919693,
-0.02395767904818058,
0.05399743467569351,
-0.00866332370787859,
0.03330082818865776,
0.03987210988998413,
0.11138596385717392,
-0.03783620893955231,
0.023765604943037033,
-0.0006808243924751878,
0.06723742932081223,
-0.005779836792498827,
0.0143... |
Individuals ’understanding of these\nissues and their physical ability to con-\nduct proper foot surveillance and care\nshould be assessed. Those with visualdifficulties, physical constraints preventing | [
-0.00911614391952753,
0.04782794415950775,
0.007359182462096214,
-0.003990993369370699,
0.014831257984042168,
0.007547926623374224,
0.040297988802194595,
0.018438229337334633,
-0.05852406471967697,
0.06362009048461914,
0.11658326536417007,
-0.027843337506055832,
-0.015187067911028862,
0.06... |
movement, or cognitive problems thatimpair their ability to assess the conditionof the foot and to institute appropriateresponses will need other people, such as\nfamily members, to assist with their care.\nThe selection of appropriate footwear\nand footwear behaviors at home should\nalso be discussed (e.g., no walking... | [
0.00671151839196682,
-0.0026125272270292044,
0.01229173969477415,
-0.04946998134255409,
-0.0030756478663533926,
0.04891408607363701,
0.04511963948607445,
0.060435786843299866,
-0.11961180716753006,
0.04978235810995102,
0.07572822272777557,
0.020546546205878258,
-0.044021736830472946,
0.031... |
also be discussed (e.g., no walking bare-\nfoot, avoiding open-toed shoes). Therapeu- | [
-0.012438426725566387,
0.028397852554917336,
-0.025934463366866112,
0.05732783302664757,
-0.003168233670294285,
-0.01454310305416584,
-0.00013334890536498278,
0.007505097892135382,
-0.08178123086690903,
0.048884209245443344,
0.12214599549770355,
0.06123536452651024,
-0.03975614160299301,
0... |
tic footwear with custom-made orthoticdevices have been shown to reduce peakplantar pressures (89). Most studies user e d u c t i o ni np e a kp l a n t a rp r e s s u r e sa sa noutcome as opposed to ulcer prevention.Certain design features of the orthoses,such as rocker soles and metatarsal ac-commodations, can reduc... | [
-0.10462450236082077,
0.04427468031644821,
0.005846148822456598,
-0.03399575129151344,
-0.015469997189939022,
0.018784290179610252,
-0.025337159633636475,
0.11770054697990417,
-0.08602139353752136,
0.056233666837215424,
0.0334586463868618,
0.035853732377290726,
0.05201995372772217,
0.03229... |
and metatarsal ac-commodations, can reduce peak plantarpressures more signi ficantly than insoles | [
-0.031544215977191925,
0.009334567934274673,
-0.03499781712889671,
0.02368287928402424,
0.04615291580557823,
-0.00563844433054328,
-0.029636533930897713,
0.11461732536554337,
-0.01975305564701557,
0.047292064875364304,
0.0832131952047348,
0.0828000083565712,
0.008502715267241001,
-0.002589... |
alone. A systematic review, however,showed there was no signi ficant reduc-\ntion in ulcer incidence after 18 monthscompared with standard insoles and extra-depth shoes. Further, it was also notedthat evidence to prevent first ulcerations\nwas nonexistent (93).\nTreatment | [
0.007424425799399614,
-0.00011140072456328198,
-0.045531462877988815,
0.09427332133054733,
0.008488142862915993,
-0.06253364682197571,
-0.039916206151247025,
0.10770875215530396,
-0.051711730659008026,
-0.06835013628005981,
0.12811821699142456,
0.04250449314713478,
0.012600983493030071,
-0... |
Treatment recommendations for peoplewith diabetes will be determined bytheir risk category. No-risk or low-risk in-dividuals can often be managed witheducation and self-care. People in themoderate to high risk category shouldbe referred to foot care specialists forfurther evaluation and regular surveil-lance as outline... | [
-0.017239639535546303,
0.03580804914236069,
-0.043390609323978424,
0.03898884356021881,
-0.03837786987423897,
-0.0010721244616433978,
0.03756692633032799,
0.08368680626153946,
-0.044825706630945206,
-0.033768150955438614,
-0.008838360197842121,
0.01992904581129551,
-0.055424947291612625,
0... |
includes individuals with LOPS, PAD,\nand/or structural foot deformities, such\nas Charcot foot, bunions, or hammer-toes. Individuals with any open ulcera-tion or unexplained swelling, erythema,or increased skin temperature shouldbe referred urgently to a foot care spe-cialist or interprofessional team.\nInitial treatm... | [
-0.0746677964925766,
-0.059185128659009933,
0.04143666476011276,
0.0040231007151305676,
-0.025944549590349197,
-0.043925847858190536,
-0.022114602848887444,
0.07958736270666122,
-0.03150131553411484,
0.02371007576584816,
0.08125526458024979,
0.015257179737091064,
-0.04459374025464058,
0.02... |
Initial treatment recommendations should\ninclude daily foot inspection, use of mois-turizers for dry, scaly skin, and avoidanceof self-care of ingrown nails and calluses.Well- fitted athletic or walking shoes with | [
-0.07875317335128784,
0.01078013889491558,
0.02663310058414936,
-0.027519172057509422,
-0.06319402158260345,
-0.07199136167764664,
-0.014412441290915012,
0.08898868411779404,
-0.09919603914022446,
-0.004665061365813017,
0.055689770728349686,
0.04961167648434639,
-0.06327718496322632,
0.066... |
customized pressure-relieving orthosesshould be part of initial recommenda-tions for people with increased plantarpressures (as demonstrated by plantarcalluses). Individuals with deformities suchas bunions or hammertoes may requirespecialized footwear such as extra-depthshoes. Those with even more signi ficant | [
-0.11032884567975998,
0.04795726761221886,
0.07227467745542526,
0.009372490458190441,
-0.023140637204051018,
0.006188996601849794,
0.02134389616549015,
0.04995410144329071,
-0.026632582768797874,
0.03555935248732567,
0.018431760370731354,
0.02566339075565338,
0.007383444812148809,
0.046398... |
deformities, as in Charcot joint disease,may require custom-made footwear.\nSpecial consideration should be given | [
-0.08463733643293381,
0.009604346938431263,
0.02691449411213398,
-0.01824190653860569,
-0.019938776269555092,
-0.027731742709875107,
-0.004346909001469612,
0.10492000728845596,
-0.06860004365444183,
0.03963630646467209,
0.06466060131788254,
0.06764870882034302,
-0.0208277590572834,
0.06192... |
to individuals with neuropathy who pre-sent with a warm, swollen, red footwith or without a history of trauma andwithout an open ulceration. These indi-viduals require a thorough workup forpossible Charcot neuroarthropathy (94).Early diagnosis and treatment of thiscondition is of paramount importancein preventing defor... | [
-0.03574300557374954,
-0.0883895605802536,
0.05030978471040726,
0.057803574949502945,
-0.07607218623161316,
-0.008428066968917847,
-0.018256090581417084,
0.10059812664985657,
-0.0785464346408844,
-0.045485664159059525,
0.06647283583879471,
0.04120290279388428,
-0.004987630527466536,
0.0622... |
of paramount importancein preventing deformities and instabilitythat can lead to ulceration and amputa-tion. These individuals require total non – | [
0.0036709348205477,
0.023352744057774544,
0.02290545031428337,
0.04015572741627693,
-0.03197665512561798,
0.03447504714131355,
0.03521191328763962,
0.06741984188556671,
-0.03609656170010567,
0.033759988844394684,
0.08346328884363174,
0.006343976128846407,
-0.006320207845419645,
0.061947587... |
weight-bearing and urgent referral to a\nfoot care specialist for further manage-\nment. Foot and ankle X-rays should beperformed in all individuals presentingwith the above clinical findings.\nThere have been a number of develop- | [
-0.05199151113629341,
-0.0029274674598127604,
0.003318557282909751,
0.02683079056441784,
-0.018146518617868423,
-0.039076678454875946,
0.01677325926721096,
0.07839825749397278,
-0.05757275968790054,
0.01909520849585533,
0.04773726314306259,
-0.01579190418124199,
-0.013973405584692955,
0.05... |
There have been a number of develop-\nments in the treatment of ulcerations overthe years (95). These include negative-pressure therapy, growth factors, bioengi-neered tissue, acellular matrix tissue, stemcell therapy, hyperbaric oxygen therapy,\nand, most recently, topical oxygen therapy\n(96–98). While there is liter... | [
0.0172576904296875,
-0.020321205258369446,
-0.015079803764820099,
0.0624435618519783,
-0.04572974890470505,
-0.043322209268808365,
-0.02878941036760807,
0.09006908535957336,
-0.05730682611465454,
-0.010333327576518059,
0.06671152263879776,
0.05696231499314308,
-0.043430425226688385,
0.0309... |
(96–98). While there is literature to sup-\nport many modalities currently used totreat diabetic foot wounds, robust ran-domized controlled trials (RCTs) are oftenlacking. However, it is agreed that the ini-tial treatment and evaluation of ulcera-tions include the following five basic\nprinciples of ulcer treatment:\n\x... | [
-0.08073186874389648,
0.013680178672075272,
-0.021892741322517395,
0.05354643985629082,
0.012810815125703812,
0.0030666699167340994,
0.000057216046116082,
0.1444806605577469,
-0.013071001507341862,
-0.025483494624495506,
0.019899500533938408,
0.06817029416561127,
-0.0456780269742012,
0.033... |
principles of ulcer treatment:\n\x81Offloading of plantar ulcerations\n\x81Debridement of necrotic, nonviable\ntissue\n\x81Revascularization of ischemic woundswhen necessary\n\x81Management of infection: soft tissueor bone\n\x81Use of physiologic, topical dressings\nHowever, despite following the above | [
-0.040513791143894196,
0.012155254371464252,
0.036092277616262436,
0.03864605724811554,
-0.04157707467675209,
0.0035713971592485905,
-0.018415944650769234,
0.09661518037319183,
-0.06467953324317932,
-0.01835636794567108,
0.07034683972597122,
0.0006164044607430696,
-0.062402188777923584,
-0... |
However, despite following the above\nprinciples, some ulcerations will becomechronic and fail to heal. In those situa-tions, advanced wound therapy can playa role. When to use advanced woundtherapy has been the subject of much\ndiscussion, as the therapy is often quite | [
-0.0365079827606678,
-0.05453870818018913,
0.024830279871821404,
0.09935469180345535,
-0.027468794956803322,
-0.013367470353841782,
-0.047411542385816574,
0.06358630955219269,
-0.020405840128660202,
0.028479240834712982,
0.06040387973189354,
0.07085742801427841,
-0.03174377605319023,
0.045... |
discussion, as the therapy is often quite\nexpensive. It has been determined thatif a wound fails to show a reduction of50% or more after 4 weeks of appropri-ate wound management (i.e., the five | [
-0.002193596912547946,
0.017368046566843987,
0.020793750882148743,
0.06542368233203888,
-0.04785419628024101,
-0.01764983870089054,
-0.0023851022124290466,
0.11123410612344742,
-0.0030787941068410873,
0.06238866597414017,
0.0659569650888443,
0.034945569932460785,
0.014937587082386017,
0.10... |
basic principles above), considerationshould be given to the use of advancedwound therapy (99). Treatment of thesechronic wounds is best managed in aninterprofessional setting.\nEvidence to support advanced wound | [
-0.06151457875967026,
-0.011751977726817131,
0.02887277491390705,
0.04441557079553604,
-0.06266892701387405,
0.01877998746931553,
-0.01594632677733898,
0.12131744623184204,
-0.09534358233213425,
0.040983639657497406,
0.019625237211585045,
0.039076924324035645,
-0.03200744092464447,
0.09486... |
Evidence to support advanced wound\ntherapy is challenging to produce and toassess. Randomization of trial participantsis dif ficult, as there are many variablesdiabetesjournals.org/care Retinopathy, Neuropathy, and Foot Care S239\n©AmericanDiabetesAssociation | [
-0.04742962121963501,
-0.028258878737688065,
0.009367549791932106,
0.06387261301279068,
0.012444094754755497,
0.03922969102859497,
-0.008060424588620663,
0.06621729582548141,
-0.11298511177301407,
0.11607212573289871,
0.027693187817931175,
0.04932193458080292,
-0.0652732402086258,
0.097685... |
that can affect wound healing. In addi-\ntion, many RCTs exclude certain cohortsof people, e.g., individuals with chronicrenal disease or those on dialysis. Finally,blinding of participants and clinicians is\nnot always possible. Meta-analyses and | [
-0.0583840049803257,
0.021653633564710617,
0.045135095715522766,
0.06838177889585495,
0.04237191751599312,
0.020070968195796013,
-0.008518015034496784,
0.12386194616556168,
-0.021903103217482567,
0.028496135026216507,
0.013946561142802238,
0.03843998908996582,
-0.030347319319844246,
0.0824... |
not always possible. Meta-analyses and\nsystematic reviews of observational stud-ies are used to determine the clinicaleffectiveness of these modalities. Such\nstudies can augment formal RCTs by in-\ncluding a greater variety of participants invarious clinical settings who are typicallyexcluded from the more rigidly st... | [
0.0014781532809138298,
0.00909514632076025,
-0.042160969227552414,
0.00382858794182539,
0.023459002375602722,
0.01898295432329178,
-0.09696360677480698,
0.13333964347839355,
0.03159405291080475,
0.03951546549797058,
-0.06325330585241318,
0.012354990467429161,
-0.016807129606604576,
0.07585... |
clinical trials.\nAdvanced wound therapy can be cate-\ngorized into nine broad categories\n(95) ( Table 12.2 ). Topical growth factors,\nacellular matrix tissues, and bioengi-\nneered cellular therapies are commonly\nused in of fices and wound care centers\nto expedite healing of chronic, more su-perficial ulcerations. N... | [
0.023126360028982162,
-0.03604196384549141,
0.016614360734820366,
0.021228795871138573,
-0.06599407643079758,
0.022275464609265327,
-0.042088016867637634,
0.12954963743686676,
-0.011270183138549328,
0.09851563721895218,
0.0016305505996569991,
0.048145610839128494,
-0.0693967342376709,
0.08... |
reports and retrospective studies havedemonstrated the clinical effectivenessof each of these modalities. Over the years,there has been increased evidence to sup-\nport the use of these modalities. Nonethe- | [
-0.046112578362226486,
-0.029815111309289932,
-0.016901718452572823,
0.03769559785723686,
-0.03654902055859566,
0.03747405484318733,
-0.04120378568768501,
0.14376157522201538,
-0.0335313118994236,
-0.050826769322156906,
0.05317330360412598,
0.10555335134267807,
-0.005653336178511381,
0.066... |
port the use of these modalities. Nonethe-\nless, use of those products or agents withrobust RCTs or systematic reviews shouldgenerally be preferred over those withoutlevel 1 evidence ( Table 12.2 ).\nNegative-pressure wound therapy was\nfirst introduced in the early to mid- | [
-0.06696999818086624,
0.019413888454437256,
-0.005486726760864258,
0.025086399167776108,
0.032892849296331406,
0.06512916088104248,
0.0022812262177467346,
0.19312527775764465,
-0.0372956246137619,
0.005704741459339857,
0.09730148315429688,
0.031150734052062035,
-0.0005993086961098015,
0.10... |
first introduced in the early to mid-\n1990s. It has become especially useful inwound preparation for skin grafts andflaps and assists in the closure of deep,\nlarge wounds (100,101). A variety oftypes exist in the marketplace andrange from electrically powered tomechanically powered in different\nsizes depending upon th... | [
-0.11958165466785431,
0.06754963099956512,
0.0016375829000025988,
0.010879486799240112,
-0.07287387549877167,
-0.01301403809338808,
0.06116539612412453,
0.13001641631126404,
-0.06619005650281906,
0.05414664372801781,
0.055024947971105576,
0.012252568267285824,
-0.0177520252764225,
0.097118... |
sizes depending upon the specifi c\nwound requirements.\nElectrical stimulation, pulsed radiofre-\nquency energy, and extracorporeal shock-\nwave therapy are biophysical modalities\nthat are believed to upregulate growth\nfactors or cytokines to stimulate woundhealing, while low-frequency noncontactultrasound is used to... | [
-0.028799081221222878,
-0.05369504541158676,
0.035183098167181015,
0.04940973222255707,
-0.08059883862733841,
0.006603097077459097,
0.025794925168156624,
0.15151070058345795,
-0.043056488037109375,
0.04442773386836052,
0.053628310561180115,
-0.08304961770772934,
0.0014452277682721615,
0.09... |
However, most of the studies advocating\nthe use of these modalities have been ret-rospective observational or poor-qualityRCTs.\nHyperbaric oxygen therapy is the de-\nlivery of oxygen through a chamber, ei-ther individual or multiperson, with theintention of increasing tissue oxygena-tion to increase tissue perfusion ... | [
-0.02647159993648529,
0.0177756417542696,
-0.02652696706354618,
0.033967215567827225,
-0.00043412469676695764,
-0.048280395567417145,
0.018012115731835365,
0.12174401432275772,
0.01594775728881359,
0.011338336393237114,
0.05124808847904205,
0.05705629289150238,
0.008863006718456745,
0.0386... |
neovascularization, combat resistant bac-\nteria, and stimulate wound healing.While there had been great interest in\nthis modality being able to expeditehealing of chronic DFUs, there has onlybeen one positive RCT published in thelast decade that reported increased heal-ing rates at 9 and 12 months comparedwith contro... | [
-0.11273135244846344,
-0.019319497048854828,
0.01530186366289854,
0.06475089490413666,
-0.04194913059473038,
0.023592326790094376,
0.00226618186570704,
0.1619214117527008,
-0.05283220112323761,
0.028114527463912964,
-0.046682924032211304,
0.027844782918691635,
-0.04445400461554527,
0.12912... |
studies with signifi cant design defi cien-\ncies and participant dropouts have failed\nto provide corroborating evidence thathyperbaric oxygen therapy should bewidely used for managing nonhealingDFUs (103,104). While there may be\nsome benefi t in prevention of amputa-\ntion in selected chronic neuroischemic\nulcers, rec... | [
-0.034773826599121094,
0.03250777721405029,
-0.006572422105818987,
0.03654322400689125,
-0.014159895479679108,
0.02294161729514599,
-0.008517835289239883,
0.11930755525827408,
-0.02498323656618595,
0.01954585500061512,
0.045044220983982086,
0.04477784410119057,
0.03199733421206474,
0.10774... |
ulcers, recent studies have shown no\nbenefit in healing DFUs in the absence of\nischemia and/or infection (98,105).\nTopical oxygen therapy has been stud-\nied rather vigorously in recent years, with\nseveral high-quality RCTs and at least five\nsystematic reviews and meta-analyses all\nsupporting its ef ficacy in healin... | [
-0.07022587209939957,
-0.02535352110862732,
0.017934396862983704,
0.09688697755336761,
0.019550630822777748,
-0.05167093127965927,
0.008562540635466576,
0.13203614950180054,
-0.0023776309099048376,
-0.06377992779016495,
-0.023002272471785545,
0.06283010542392731,
-0.02432342991232872,
0.06... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.